S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
S&P 500   3,933.92
DOW   33,597.92
QQQ   280.53
How To Be Persuasive With Your Body Language
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
How to Play Apple and Amazon Heading in 2023
Low Beta, High Yield Campbell Soup Company Is Mmm Mmm Good
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Microsoft strikes 10-year deal with Nintendo on Call of Duty
Could trawler cams help save world's dwindling fish stocks?
"TAKE THAT, CHINA!" USA Gains in EV Battery Arms Race (Ad)
Southwest Airlines brings back dividend as travel rebounds
Closing prices for crude oil, gold and other commodities
NASDAQ:NYMX

Nymox Pharmaceutical - NYMX Stock Forecast, Price & News

$0.50
+0.08 (+19.27%)
(As of 12/7/2022 12:00 AM ET)
Add
Compare
Today's Range
$0.42
$0.52
50-Day Range
$0.29
$0.50
52-Week Range
$0.19
$2.10
Volume
355,824 shs
Average Volume
299,764 shs
Market Capitalization
$44.82 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
NYMX stock logo

About Nymox Pharmaceutical (NASDAQ:NYMX) Stock

Nymox Pharmaceutical Corporation, a biopharmaceutical company, engages in the research and development of drugs for the aging population in Canada, the United States, Europe, and internationally. Its lead drug candidate is Fexapotide Triflutate (NX-1207), which has completed Phase III clinical trials for the treatment of benign prostatic hyperplasia, and Phase II clinical trials for low grade localized prostate cancer, as well as is in preclinical studies for hepatocellular carcinoma. The company also develops and markets NicAlert and TobacAlert tests that use urine or saliva to detect use of tobacco products. In addition, it offers AlzheimAlert, a proprietary urine assay that aids physicians in the diagnosis of Alzheimer's disease, as well as researches and develops drug treatments for Alzheimer's disease. The company was founded in 1989 and is headquartered in Nassau, the Bahamas.

Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Stock News Headlines

NYMOX Updates Shareholders
NYMOX Receives Deficiency Letter from NASDAQ
Executives Buy Around $5M Of 4 Penny Stocks
Nymox Announces Closing of $6.4 Million Financing
Nymox Direct Offering
Nymox Announces $5 Million Registered Direct Offering
See More Headlines
Receive NYMX Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Nymox Pharmaceutical and its competitors with MarketBeat's FREE daily newsletter.

NYMX Company Calendar

Last Earnings
11/14/2022
Today
12/08/2022
Fiscal Year End
12/31/2022
Next Earnings (Estimated)
3/29/2023

Industry, Sector and Symbol

Industry
Diagnostic substances
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:NYMX
Employees
3
Year Founded
N/A

Profitability

Net Income
$-12,540,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.01) per share

Miscellaneous

Free Float
41,637,000
Market Cap
$44.82 million
Optionable
Optionable
Beta
0.67

Key Executives

  • Dr. Paul Averback DABP (Age 71)
    M.D., Founder, Chairman, CEO & Pres
    Comp: $750k
  • Mr. Randall J. Lanham Esq. (Age 58)
    J.D., Gen. Counsel, Sec., COO & Director
    Comp: $435.29k
  • Ms. Lin Dodd
    QA and Compliance Mang.













NYMX Stock - Frequently Asked Questions

How have NYMX shares performed in 2022?

Nymox Pharmaceutical's stock was trading at $1.30 at the beginning of the year. Since then, NYMX stock has decreased by 61.9% and is now trading at $0.4952.
View the best growth stocks for 2022 here
.

When is Nymox Pharmaceutical's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Wednesday, March 29th 2023.
View our NYMX earnings forecast
.

How were Nymox Pharmaceutical's earnings last quarter?

Nymox Pharmaceutical Co. (NASDAQ:NYMX) issued its quarterly earnings results on Monday, November, 14th. The biopharmaceutical company reported ($0.02) earnings per share (EPS) for the quarter.

What other stocks do shareholders of Nymox Pharmaceutical own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Nymox Pharmaceutical investors own include Quantum (QTM), Rocket Pharmaceuticals (RCKT), Biocept (BIOC), TherapeuticsMD (TXMD), Catalyst Pharmaceuticals (CPRX), MEI Pharma (MEIP), OPKO Health (OPK), Rigel Pharmaceuticals (RIGL), Synergy Pharmaceuticals (SGYP) and CTI BioPharma (CTIC).

What is Nymox Pharmaceutical's stock symbol?

Nymox Pharmaceutical trades on the NASDAQ under the ticker symbol "NYMX."

Who are Nymox Pharmaceutical's major shareholders?

Nymox Pharmaceutical's stock is owned by many different institutional and retail investors. Top institutional investors include Group One Trading L.P. (0.00%).
View institutional ownership trends
.

How do I buy shares of Nymox Pharmaceutical?

Shares of NYMX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Nymox Pharmaceutical's stock price today?

One share of NYMX stock can currently be purchased for approximately $0.50.

How much money does Nymox Pharmaceutical make?

Nymox Pharmaceutical (NASDAQ:NYMX) has a market capitalization of $44.82 million. The biopharmaceutical company earns $-12,540,000.00 in net income (profit) each year or ($0.10) on an earnings per share basis.

How can I contact Nymox Pharmaceutical?

Nymox Pharmaceutical's mailing address is BAY & DEVEAUX STREETS, NASSAU C5, H4M 2V2. The official website for the company is www.nymox.com. The biopharmaceutical company can be reached via phone at (800) 936-9669, via email at info@nymox.com, or via fax at 514-332-2227.

This page (NASDAQ:NYMX) was last updated on 12/8/2022 by MarketBeat.com Staff